Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,018 public trials 2,029 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

NCT02763319

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • MorphoSys Research Site Anaheim, California, United States
  • MorphoSys Research Site Bakersfield, California, United States
  • Morphosys Research Site Burbank, California, United States
  • Morphosys Research Site Fresno, California, United States
View all 158 locations
View Trial Details
Completed

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

NCT06055075

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Princess Alexandra Hospital Woolloongabba Woolloongabba, Queensland, Australia
  • Royal Adelaide Hospital Adelaide, South Australia, Australia
  • Hamilton Health Sciences Hamilton, Ontario, Canada
  • Istituto Clinico Humanitas Rozzano, Lombardy, Italy
View Trial Details
Completed

A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

NCT03144674

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • University of Alabama At Birmingham Comprehensive Cancer Center Birmingham, Alabama, United States
  • Arizona Oncology Associates Tempe, Arizona, United States
  • Torrance Health Association Redondo Beach, California, United States
  • Sansum Clinic Santa Barbara, California, United States
View all 86 locations
View Trial Details
Completed

Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.

NCT01996865

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • Local Institution - 055 Tucson, Arizona, United States
  • Local Institution - 077 Little Rock, Arkansas, United States
  • Local Institution - 079 Berkeley, California, United States
  • Local Institution - 142 Concord, California, United States
View all 126 locations
View Trial Details
Completed

New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement

NCT02329080

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Facultni nemocnice Brno, Czechia
  • FNKV (Facultni Nemocnice Kralovske Vinohrady) Prague, Czechia
  • Vseobecna facultni nemocnice v Praze Prague, Czechia
  • Spedali Civili Brescia, Italy
View all 36 locations
View Trial Details
Completed

CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7

NCT00812669

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +13 more
Locations
  • Tallaght University Hospital Dublin, Leinster, Ireland
  • Cork University Hospital Cork, Munster, Ireland
  • St. James's Hospital Dublin, Ireland
  • University College Hospital Galway, Ireland
View Trial Details
Completed

A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT01776840

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Tucson, Arizona, United States
  • Burbank, California, United States
  • La Jolla, California, United States
  • Stanford, California, United States
View all 201 locations
View Trial Details

Related conditions